Array BioPharma Says Encouraging Selumetinib Results Announced for Phase 2 Trial in Ovarian Cancer
The Gynecologic Oncology Group presented results of a Phase 2 trial with selumetinib, a small-molecule MEK inhibitor, in women with recurrent low-grade serous ovarian or peritoneal cancer at the American Association for Cancer Research Annual Meeting 2012 on Monday, April 2, 2012. Selumetinib was invented by Array BioPharma Inc. (NASDAQ: ARRY) and licensed to AstraZeneca. This trial was funded by the National Cancer Institute and run by the Gynecologic Oncology Group.
In the reported trial, 52 women each received 100-mg doses of selumetinib orally twice daily in four-week cycles until disease progression or toxicity. The median number of cycles received was 4.5; 33% underwent 12 or more cycles. Prior to the trial, 58% of the patients in the trial had received three or more rounds of chemotherapy.
The Gynecological Oncology Group reported a disease control rate, defined as either complete or partial response or progression-free survival or progression-free survival of greater than 6 months, of 81% of patients. Eight patients had complete (1) or partial (7) responses, and 34 (63%) had progression-free survival of greater than 6 months. The median survival rate without cancer progression was 11 months. Only three patients experienced grade 4 adverse events.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.